

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A prodrug 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1*H*-imidazole or a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

Claims 2-3. (Canceled).

4. (Currently Amended) The ~~compound~~ prodrug according to claim 1, wherein the compound is 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1*H*-imidazol-1-ium chloride.

Claims 5-6. (Canceled).

7. (Currently Amended) A method for the treatment of hypertension, glaucoma, migraine, diarrhea, ischemia, addiction to a chemical substance, hypotension, shock, cardiopulmonary resuscitation, a withdrawal syndrome, congestive heart failure, anxiety, or for achieving sedation or analgesia, or for reducing nasal congestion, or for achieving anesthesia with an adjunct, which comprises administering to a mammal in need thereof an effective amount of a prodrug 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1*H*-imidazole or a pharmaceutically acceptable salt ~~or hydrate~~ thereof.

8. (Currently Amended) The method according to claim 7, wherein the ~~compound~~ prodrug is 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1*H*-imidazol-1-ium chloride.

9. (Currently Amended) A pharmaceutical composition which comprising a prodrug 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1*H*-imidazole or a

pharmaceutically acceptable salt or hydrate thereof, and optionally a pharmaceutically acceptable excipient.

10. (Currently amended) The pharmaceutical composition according to claim 9, wherein the compound prodrug is 4-[6-(2,2-dimethylpropanoyloxy)indan-1-ylmethyl]-1H-imidazol-1-ium chloride.

Claims 11-12. (Canceled).